Company search
Overview
Performance
Portfolio
ESG
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Unlisted holdings
Data as at : 31/03/2024
| % of total assets |
|---|
| 8.0 |
Please note that the percentage of unlisted holdings is displayed for companies that have reported this data to the AIC. “N/R” means the data has not been reported to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 31/03/2024
| Investment | % of total assets |
|---|---|
| Amgen Inc | 5.6 |
| Cytokinetics Inc | 5.1 |
| Sv Fund Vi Investment | 4.8 |
| Gilead Sciences Inc | 4.4 |
| Vera Therapeutics Inc Class A | 4.3 |
| Biomarin Pharmaceutical Inc | 4.3 |
| Incyte Corp | 3.7 |
| Supernus Pharmaceuticals Inc | 3.5 |
| Alnylam Pharmaceuticals Inc | 3.4 |
| Scb Sholo211123b 20-Mar-2024 6.46% 22-Apr-2024 | -10.0 |
Geographic breakdown
Data as at : 31/03/2024
| Country | % of total assets |
|---|---|
| USA | 77.9 |
| Bermuda | 5.6 |
| Netherlands | 4.5 |
| UK | 3.1 |
| Canada | 2.4 |
| Denmark | 1.9 |
| Ireland | 1.9 |
| Germany | 1.2 |
| Sweden | 0.5 |
| Switzerland | 0.4 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 31/03/2024
| Industry | % of total assets |
|---|---|
| Healthcare | 100.9 |
| Consumer Defensive | 0.4 |
| Preferred | 0.3 |
Scroll
Asset breakdown
Data as at : 31/03/2024
| Asset | % of total assets |
|---|---|
| Stock | 103.1 |
| Other | 6.9 |
| Bond | -10.0 |
Detailed asset breakdown
Data as at : 31/03/2024
| Asset | % of total assets |
|---|---|
| North America - stock | 86.6 |
| Other | 6.9 |
| Asia (excl Japan) - stock | 3.9 |
| Other - stock | 3.6 |
| Europe - Small-cap stock | 3.1 |
| UK - Large growth stock | 2.6 |
| Europe - Large-cap stock | 2.1 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
